PET-ART
PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
Rekrutierend
NCT-Nummer:
NCT06247163
Studienbeginn:
Februar 2024
Letztes Update:
18.03.2024
Wirkstoff:
-
Indikation (Clinical Trials):
Small Cell Lung Carcinoma
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
-
Sponsor:
University Hospital, Essen
Collaborator:
-
Detailed Description:
The main objective of this study is to determine whether patients with SCLC who have a
metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to
three cycles of induction chemotherapy have a similarly low local recurrence rate with higher
dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for
definitive radiotherapy of locally advanced small cell lung cancer within the corridor
recommended as standard therapy according to the current interdisciplinary S3 guideline of
the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor
rest by PET CT and biopsy.
Inclusion Criteria:
- Histopathologic confirmation
- Limited disease
Exclusion Criteria:
- Other histology than small cell lung cancer
- Further tumor diagnosis
- ECOG 3 or worse
- Extensive disease
- stage IV
Primary outcome:
1. Local recurrence free survival (Time Frame - 2 months to 5 years):
Local recurrence free survival
2. Distant recurrence free survival (Time Frame - 2 months to 5 years):
Distant recurrence free survival
3. Overall survival (Time Frame - 2 months to 5 years):
Overall survival
- PET based Raditherapy boost:
An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"PET-guided Radiotherapy for Patients With Small Cell Lung Cancer."
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!
